DR. RICHARD ADAM MESSMANN, M.D.
Osteopathic Medicine at Hartford Way, Brighton Twp, MI

License number

Michigan 4301057954

Personal information

See more information about RICHARD ADAM MESSMANN at radaris.com

Name

Address

Phone

Richard Messmann

1011 Hickory Dr, Brighton, MI 48116

Richard Messmann

5912 Hartford Way, Brighton, MI 48116

Richard Messmann

1011 Hickory Dr, Brighton, MI 48116

Richard Messmann

4455 Heritage Ave, Okemos, MI 48864

Richard Messmann

4608 Huntington Dr, Brighton, MI 48116

Organization information

See more information about RICHARD ADAM MESSMANN at bizstanding.com

Richard Adam Messmann M.D

5912 Hartford Way, Brighton Twp, MI 48116

Industry:

Business Consulting Services

Medical Doctor, Principals:

Richard A. Messman (Medical Doctor),Richard A. Messmann Medical Doctor, Principal, inactive

Professional information

See more information about RICHARD ADAM MESSMANN at trustoria.com

Folate-Targeted Diagnostics And Treatment

US Patent:

2012012, May 24, 2012

Filed:

Jul 30, 2010

Appl. No.:

13/388184

Inventors:

Christopher Paul Leamon - West Lafayette IN, US
Richard Messmann - Brighton MI, US
David Morgenstern - Indianapolis IN, US

Assignee:

ENDOCYTE, INC. - West Lafayette IN

International Classification:

A61K 51/08, A61P 35/04, A61P 35/00, A61K 38/08, A61K 9/127

US Classification:

424 169, 514 193, 424450

Abstract:

Methods of detecting and assessing functionally active folate receptors on tumors and treatment associated with those tumors are described. Also described are methods of selecting ovarian and lung cancer patients for therapy with a folate-vinca conjugate by identifying functionally active folate receptors on the tumors of the patient. Also described are methods and compositions for treating folate receptor expressing epithelial tumors with a folate-vinca conjugate in combination with doxorubicin such as pegylated liposomal doxorubicin in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum sensitive ovarian tumors. Also described are methods of treating platinum-resistant ovarian cancer using a folate-targeted drug, in the absence or presence of selecting the patient by identifying functionally active folate receptors on the tumors of the patient.